CSP-2503
Izgled
(IUPAC) ime | |||
---|---|---|---|
2-[(4-naftalen-1-ilpiperazin-1-il)metil]heksahidropirolo[1,2-a]pirazin-1,4-dion | |||
Klinički podaci | |||
Identifikatori | |||
ATC kod | nije dodeljen | ||
PubChem[1][2] | 10317515 | ||
ChemSpider[3] | 8492979 | ||
ChEMBL[4] | CHEMBL285066 | ||
Hemijski podaci | |||
Formula | C22H26N4O2 | ||
Mol. masa | 378,47 g/mol | ||
SMILES | eMolekuli & PubHem | ||
| |||
Farmakoinformacioni podaci | |||
Trudnoća | ? | ||
Pravni status |
CSP-2503 je potentan i selektivan agonist 5-HT1A receptora, i antagonist 5-HT2A receptor i 5-HT3 receptora.[5] On je prvi put sintetisan 2003 koristeći dizajn baziran na računarskom modelu i QSAR studijama.[6][7] U istraživanjima na pacovima, CSP-2503 je pokazao anksiolitičko dejstvo, te je smatra da može da služi kao potencijalni tretman za anksioznost kod ljudi, sa multimodalnim mehanizmom dejstva.[5]
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ 5,0 5,1 Delgado M, Caicoya AG, Greciano V, et al. (March 2005). „Anxiolytic-like effect of a serotonergic ligand with high affinity for 5-HT1A, 5-HT2A and 5-HT3 receptors”. European Journal of Pharmacology 511 (1): 9–19. DOI:10.1016/j.ejphar.2005.01.032. PMID 15777774.
- ↑ López-Rodríguez ML, Morcillo MJ, Fernández E, et al. (April 2003). „Design and synthesis of S-(-)-2-[[4-(napht-1-yl)piperazin-1-ylmethyl]-1,4-dioxoperhydropyrrolo[1,2-a]pyrazine (CSP-2503) using computational simulation. A 5-HT1A receptor agonist”]. Bioorganic & Medicinal Chemistry Letters 13 (8): 1429–32. DOI:10.1016/S0960-894X(03)00160-4. PMID 12668005.
- ↑ López-Rodríguez ML, Morcillo MJ, Fernández E, et al. (April 2005). „Synthesis and structure-activity relationships of a new model of arylpiperazines. 8. Computational simulation of ligand-receptor interaction of 5-HT(1A)R agonists with selectivity over alpha1-adrenoceptors”. Journal of Medicinal Chemistry 48 (7): 2548–58. DOI:10.1021/jm048999e. PMID 15801844.